Chou Associates Management Inc. Has $383,000 Position in GlaxoSmithKline PLC (GSK)
Chou Associates Management Inc. continued to hold its stake in GlaxoSmithKline PLC (NYSE:GSK) during the third quarter, Holdings Channel reports. The institutional investor owned 18,000 shares of the pharmaceutical company’s stock at the end of the third quarter. GlaxoSmithKline PLC accounts for 0.1% of Chou Associates Management Inc.’s holdings, making the stock its 24th largest position. Chou Associates Management Inc.’s holdings in GlaxoSmithKline PLC were worth $383,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the company. Thrivent Financial for Lutherans raised its stake in GlaxoSmithKline PLC by 3.8% in the second quarter. Thrivent Financial for Lutherans now owns 2,651 shares of the pharmaceutical company’s stock valued at $115,000 after buying an additional 96 shares during the last quarter. SevenBridge Financial Group LLC acquired a new stake in GlaxoSmithKline PLC during the second quarter valued at about $116,000. Quadrant Capital Group LLC raised its stake in GlaxoSmithKline PLC by 6.4% in the second quarter. Quadrant Capital Group LLC now owns 2,725 shares of the pharmaceutical company’s stock valued at $111,000 after buying an additional 163 shares during the last quarter. Signaturefd LLC raised its stake in GlaxoSmithKline PLC by 25.2% in the second quarter. Signaturefd LLC now owns 3,020 shares of the pharmaceutical company’s stock valued at $131,000 after buying an additional 607 shares during the last quarter. Finally, Clean Yield Group raised its stake in GlaxoSmithKline PLC by 42.4% in the third quarter. Clean Yield Group now owns 3,360 shares of the pharmaceutical company’s stock valued at $145,000 after buying an additional 1,000 shares during the last quarter. 8.48% of the stock is owned by institutional investors.
GlaxoSmithKline PLC (NYSE:GSK) traded up 0.54% on Friday, reaching $39.22. 3,228,108 shares of the company’s stock were exchanged. The stock has a market capitalization of $95.42 billion, a PE ratio of 261.47 and a beta of 0.90. GlaxoSmithKline PLC has a 12 month low of $37.20 and a 12 month high of $45.58. The firm has a 50 day moving average of $38.39 and a 200 day moving average of $41.56.
The firm also recently announced a dividend, which was paid on Thursday, January 12th. Shareholders of record on Friday, November 4th were paid a $0.459 dividend. The ex-dividend date was Wednesday, November 2nd. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 1,525.00%.
COPYRIGHT VIOLATION WARNING: This news story was first reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The legal version of this news story can be viewed at http://www.watchlistnews.com/chou-associates-management-inc-has-383000-position-in-glaxosmithkline-plc-gsk/1060940.html.
Several equities research analysts have recently issued reports on the stock. Goldman Sachs Group, Inc. (The) reissued a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Wednesday, December 21st. Deutsche Bank AG reissued a “hold” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, October 27th. Investec assumed coverage on shares of GlaxoSmithKline PLC in a research report on Thursday, October 20th. They issued a “buy” rating for the company. Zacks Investment Research raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $43.00 price objective for the company in a research report on Tuesday, December 27th. Finally, Beaufort Securities reaffirmed a “buy” rating on shares of GlaxoSmithKline PLC in a report on Friday, September 16th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and twelve have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $47.00.
In other GlaxoSmithKline PLC news, major shareholder Plc Glaxosmithkline bought 66,500 shares of GlaxoSmithKline PLC stock in a transaction on Monday, October 24th. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $931,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.00% of the stock is currently owned by company insiders.
About GlaxoSmithKline PLC
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.